Hjem › Steatotisk leversykdom › Nevada
Kliniske studier for Steatotisk leversykdom i Nevada
7 studier for Steatotisk leversykdom søker deltakere på steder i Nevada.
Byer i Nevada
Offisiell studietekst (engelsk)
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Jubilee Clinical Research NV. LLC, Las Vegas
- Excel Clinical Research, LLC, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Las Vegas
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Jubilee Clinical Research, Inc, Las Vegas
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Las Vegas
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Las Vegas
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Las Vegas
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Las Vegas
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT07221227Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.